Technology

AC Immune

$6.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.25 (+4.22%) Today
$0.00 (0.00%) As of 9:04 PM UTC after-hours

Why Robinhood?

You can buy or sell AC Immune and other stocks, options, and ETFs commission-free!

About ACIU

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland. The listed name for ACIU is AC Immune SA Common Stock.

CEO
Andrea Pfeifer
Employees
132
Headquarters
Lausanne, Vaud
Founded
2003
Market Cap
433.60M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
507.77K
High Today
$6.30
Low Today
$5.85
Open Price
$6.08
Volume
171.65K
52 Week High
$13.00
52 Week Low
$4.07

Collections

ACIU Earnings

-$0.28
-$0.10
$0.08
$0.26
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 29, Pre-Market

You May Also Like

BRLI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure